(Q39572401)

13 September 2017

title

Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome (English)

1 reference

13 September 2017

Mark C Bagley

1

1 reference

13 September 2017

Terence Davis

2

1 reference

13 September 2017

Michal J Rokicki

3

1 reference

13 September 2017

Caroline S Widdowson

4

1 reference

13 September 2017

David Kipling

5

1 reference

13 September 2017

publication date

1 February 2010

1 reference

Future Medicinal Chemistry

13 September 2017

published in

1 reference

13 September 2017

volume

2

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

193-201

1 reference

p38(MAPK): stress responses from molecular mechanisms to therapeutics

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

p38 MAP-kinases pathway regulation, function and role in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

The biology of p38 kinase: a central role in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Anti-TNF-alpha therapies: the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Inhibition of p38: has the fat lady sung?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

The discovery of novel chemotypes of p38 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

What geriatricians should know about the Werner syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Positional cloning of the Werner's syndrome gene

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

What can progeroid syndromes tell us about human aging?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Replicative senescence: an old lives' tale?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

How might replicative senescence contribute to human ageing?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Normal telomere erosion rates at the single cell level in Werner syndrome fibroblast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Prevention of accelerated cell aging in the Werner syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

The role of cellular senescence in Werner syndrome: toward therapeutic intervention in human premature aging

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Werner Syndrome as an example of inflamm-aging: possible therapeutic opportunities for a progeroid syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Microwave-assisted synthesis of N-pyrazole ureas and the p38alpha inhibitor BIRB 796 for study into accelerated cell ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Dissection of the recognition properties of p38 MAP kinase. Determination of the binding mode of a new pyridinyl-heterocycle inhibitor family

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.09.163

21 January 2018

Identifiers

DOI

10.4155/FMC.09.163

1 reference

13 September 2017

1 reference